BRAF and colorectal cancer: As it is essential to consider ITH during preclinical development of anticancer therapeutics (19), we chose a panel of colorectal cancer PDOs spanning genetic (e.g., MSI/MSS and KRAS/BRAF /APC status), clinical stage, anatomic location, chemosensitivity, and CSC composition.